Skip to main content
Premium Trial:

Request an Annual Quote

Priority One, Iowa Industrial New Jobs Training Program, Iowa Department of Economic Development, Canyon Park, CenterPark Plaza, Akridge, Seaton Benkowski and Partners, Eurofins Genomics

Genencor International Sets $3.5M Expansion of Cedar Rapids, Iowa, Production Facility
Genencor International, a developer of enzymes for the bioproducts market, announced plans Dec. 14 for a $3.5 million expansion that will add a new applications laboratory with a pilot plant and a training center to its largest North American production plant in Cedar Rapids, Iowa.
The unit of Copenhagen-based Danisco A/S said it would build a 20,000-square-foot “Center of Excellence” addition to its plant on 80 acres at 1000 41st Avenue Drive, Southwest. The new facility — to focus on development of fuel ethanol and processing of sweeteners made from corn — will allow Genencor to add 20 staffers to its current Cedar Rapids workforce.
“Danisco sees enzymes as a growth engine for the company," Troy Wilson, Genencor’s vice president of grain processing, told the Cedar Rapids Gazette. "The business is growing at a minimum of 5 percent per year."
Construction is set to start early in 2008, with the addition set for completion by fall 2008 or early 2009. The Cedar Rapids facility supplies the North American market with enzymes and bioproducts for the cleaning, textiles, fuels, and chemical industries.
Genencor is pursuing tax credits, property tax exemptions, and other economic incentives for the expansion from a trio of agencies: The Priority One economic development division of the city of Cedar Rapids, the Iowa Industrial New Jobs Training Program administered through Kirkwood Community College, and the Iowa Department of Economic Development.

CellCyte Genetics Corp. Completes Move of Corporate HQ to Bothell, Wash.
CellCyte Genetics has completed its move from Kirkland, Wash., to Bothell, Wash., where it has combined all its corporate and administrative, R&D, imaging, manufacturing and support operations into a renovated 26,500-square-foot facility within the Canyon Park biotechnology complex.
CellCyte acquired the new facility in May, then spent the following seven months renovating the site. The facility now houses four full-scale research laboratories; three tissue culture labs for the growth and expansion of stem cells; a specialized "hot lab" for the radioactive labeling of cells; two laboratories dedicated to device manufacturing, cell expansion and stem cell purification; a dedicated nuclear imaging suite incorporating the SPECT/CT camera; a full animal research vivarium facility; support services; and CellCyte’s corporate offices.
CellCyte Genetics said in a statement its new facility would serve as its main research facility for carrying out preclinical studies and developing its pipeline of products. The company develops therapeutic products based on adult stem cells.

Biotech Adds R&D Space, Expands Within San Diego’s CenterPark Plaza
Cyntellect, a San Diego-based company focused on commercializing laser-based live-cell manipulation systems, has expanded to 23,409 square feet and renovated its R&D space at 6620 Mesa Ridge Road in the Sorrento Mesa section of San Diego, part of the nine-building, 203,761-square-foot CenterPark Plaza R&D/office park owned by the real estate company RREEF, under a 62-month lease valued at $1.72 million, the San Diego Business Journal reported.
Glenn Friedrich of CresaPartners represented Cyntellect in the deal, while Christopher High, Michael Macie, Eric Northbrook, and Jeff Oesterblad of Cushman & Wakefield represented RREEF. In 2005, Cyntellect took 9,169 square feet in the building, under a 60-month lease valued at $738,288.

$66M in Permanent Financing Secured for Washington, DC, home of EMD Serono
Real estate services company Akridge and real estate investment firm Seaton Benkowski and Partners have closed on $66 million in permanent financing with MetLife for Carroll Square, the class A office building at 975 F St., NW, in downtown Washington, DC, next to historic St. Patrick's Church. Tenants in the 10-story, 170,000 square-foot building include Merck affiliate EMD Serono. building at 975 F St., NW, in downtown Washington, DC, next to historic St. Patrick's Church. Tenants in the 10-story, 170,000 square-foot building include Merck affiliate EMD Serono.

Eurofins to Close Three Facilities as Three Subsidiaries Form Genomics Joint Venture
The Eurofins Group, an international bioanalytical testing provider, has formed a genomics business unit called Eurofins Genomics that will consolidate the operations of Operon Biotechnologies, which it recently acquired, and two existing Eurofins subsidiaries, MWG Biotech and Medigenomix, BRN sister publication GenomeWeb Daily News reported.
Over the next year, Medigenomix’s Martinsried, Germany, operations will move to nearby Ebersberg, where MWG is headquartered. Also moving to Ebersberg will be operations now based in Operon’s facilities in Köln, Germany, which will be closed. MWG’s US operations in High Point, NC, will move to Huntsville, Ala., where they will merge with Operon’s existing location.
The closures are part of Eurofins Genomics’ plan to consolidate and align assets after its recent purchase of Operon Biotechnologies, said Jutta Huber, MWG’s head of marketing.
Huber said that the consolidation is partly in response to a competitive but, in terms of organic growth, “not very dynamic” oligonucleotide synthesis market. 
In a statement, Patrick Weiss, Operon’s managing director and the new CEO of Eurofins Genomics, said that “overcapacity in the market has put a lot of pressure on oligonucleotide synthesis service suppliers,” and that “very few companies are able to keep up with the level of investment and innovation needed to meet the market demand.”
“It is a very competitive market,” Weiss told GWDN, “[but] with every competitor that we take out there is less competition.”

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.